Director Todd S. Thomson and affiliated Kairos entities filed a joint Form 4 with the SEC on November 2, 2026, reporting the acquisition of warrants to purchase an aggregate of 700,000 shares of Actuate Therapeutics, Inc. common stock at an exercise price of $0.5325, with a transaction date of October 28, 2026.

Key Highlights

  • Total warrants acquired: 700,000 warrants to purchase common stock were issued in aggregate to four Kairos Funds on October 28, 2026.
  • Exercise price: Each warrant carries a conversion/exercise price of $0.5325 per share.
  • Allocation across funds: Kairos Venture Partners II, LP received 269,017 warrants; Kairos Venture Opportunities I, L.P. received 259,572; Kairos-Actuate SPV, L.P. received 75,738; and Kairos SPV Fund, LLC received 95,673.
  • Lock-up consideration: According to the filing, the warrants were issued in consideration for the Kairos Funds agreeing not to sell, transfer, or dispose of Actuate shares for two years from the close of Actuate's public offering on October 28, 2026.
  • Warrant terms: The filing states the warrants were immediately exercisable upon issuance and expire five years after the closing of the offering.
  • Reporting persons: The joint filing covers Todd S. Thomson (director), Kairos Venture Investments, LLC, and the four Kairos Funds, with James T. Demetriades, CEO of KVI, signing as authorized signatory for each entity.
  • Indirect ownership: All warrant positions are held indirectly, with each fund listed as the direct holder; the filing notes that Thomson and Demetriades disclaim beneficial ownership except to the extent of their pecuniary interest.

Kairos Funds Receive Lock-Up Warrants from Actuate Therapeutics Following October 2026 Offering

According to the Form 4 filed on NASDAQ:ACTU, Actuate Therapeutics, Inc. issued an aggregate of 700,000 warrants to purchase common stock to four affiliated investment funds collectively referred to in the filing as the "Kairos Funds." The transaction date was October 28, 2026, coinciding with the closing of Actuate's public offering of common stock. The filing reports that the warrants carry an exercise price of $0.5325 per share, were immediately exercisable upon issuance, and expire five years after the offering's close.

The filing explains that the warrants were granted "in consideration for an agreement between Actuate and the Kairos Funds pursuant to which the Kairos Funds agreed, subject to certain limited exceptions, not to sell, transfer or dispose of, directly or indirectly, any shares of Actuate's common stock beneficially owned by them" for a period of two years from the close of the offering. The four funds receiving the warrants are Kairos Venture Partners II, LP (269,017 warrants), Kairos Venture Opportunities I, L.P. (259,572 warrants), Kairos-Actuate SPV, L.P. (75,738 warrants), and Kairos SPV Fund, LLC (95,673 warrants).

The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), according to the filing. Todd Thomson serves as CFO/COO of KVI and as a director on Actuate's board. James Demetriades is identified as KVI's CEO. The filing notes that each of KVI, Thomson, and Demetriades "may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds," while each disclaims beneficial ownership beyond their respective pecuniary interests. The other reporting persons are deemed directors of Actuate "by deputization" due to their relationship with Thomson, according to the filing's remarks.

What Was Disclosed

A joint Form 4 reported the October 28, 2026 acquisition of an aggregate 700,000 warrants to purchase Actuate Therapeutics common stock at $0.5325, distributed across four Kairos-affiliated funds managed by KVI, in connection with a two-year lock-up agreement tied to Actuate's public offering.